- Home
- ATEX vs RLAY Comparison
ATEX vs RLAY Comparison
Compare ATEX & RLAY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ATEX
- RLAY
- Stock Information
- Founded
- ATEX 1997
- RLAY 2015
- Country
- ATEX United States
- RLAY United States
- Employees
- ATEX N/A
- RLAY N/A
- Industry
- ATEX Telecommunications Equipment
- RLAY Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- ATEX Telecommunications
- RLAY Health Care
- Exchange
- ATEX Nasdaq
- RLAY Nasdaq
- Market Cap
- ATEX 528.1M
- RLAY 490.3M
- IPO Year
- ATEX N/A
- RLAY 2020
- Fundamental
- Price
- ATEX $27.52
- RLAY $3.18
- Analyst Decision
- ATEX Buy
- RLAY Strong Buy
- Analyst Count
- ATEX 2
- RLAY 11
- Target Price
- ATEX $64.00
- RLAY $18.40
- AVG Volume (30 Days)
- ATEX 124.7K
- RLAY 1.6M
- Earning Date
- ATEX 08-05-2025
- RLAY 08-05-2025
- Dividend Yield
- ATEX N/A
- RLAY N/A
- EPS Growth
- ATEX N/A
- RLAY N/A
- EPS
- ATEX N/A
- RLAY N/A
- Revenue
- ATEX $5,902,000.00
- RLAY $7,679,000.00
- Revenue This Year
- ATEX $49.39
- RLAY $14.31
- Revenue Next Year
- ATEX $2.84
- RLAY N/A
- P/E Ratio
- ATEX N/A
- RLAY N/A
- Revenue Growth
- ATEX 66.77
- RLAY N/A
- 52 Week Low
- ATEX $25.32
- RLAY $1.78
- 52 Week High
- ATEX $42.91
- RLAY $10.72
- Technical
- Relative Strength Index (RSI)
- ATEX 45.47
- RLAY 55.48
- Support Level
- ATEX $26.63
- RLAY $2.98
- Resistance Level
- ATEX $28.63
- RLAY $3.48
- Average True Range (ATR)
- ATEX 0.94
- RLAY 0.25
- MACD
- ATEX 0.21
- RLAY -0.00
- Stochastic Oscillator
- ATEX 63.20
- RLAY 58.45
About ATEX Anterix Inc.
Anterix Inc is a United States-based company engaged in delivering broadband needed to modernize infrastructure for energy, transportation, logistics, and other industries. The company offers Private LTE for utilities which help to automate processes, monitor environmental conditions, enable artificial intelligence, and drive productivity.
About RLAY Relay Therapeutics Inc.
Relay Therapeutics Inc is a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies with the goal of bringing life-changing therapies to patients. the Dynamo platform integrates an array of leading-edge computational and experimental approaches designed to drug-protein targets that have previously been intractable or inadequately addressed. The company is advancing a pipeline of medicine candidates to address targets in precision oncology and genetic disease, including product candidates, RLY-4008, RLY-2608, and GDC-1971 (formerly known as RLY-1971).